670
Participants
Start Date
February 25, 2021
Primary Completion Date
March 27, 2024
Study Completion Date
March 27, 2024
Omadacycline
IV for injection, oral tablets
Moxifloxacin
IV solution, oral tablets
Site 210, Gabrovo
Site 213, Lom
Site 208, Pernik
Site 201, Pleven
Site 206, Rousse
Site 207, Sliven
Site 202, Sofia
Site 204, Sofia
Site 205, Sofia
Site 209, Sofia
Site 212, Vidin
Site 211, Vratsa
Site 302, Split
Site 301, Zagreb
Site 303, Zagreb
Site 304, Zagreb
Site 401, Tbilisi
Site 402, Tbilisi
Site 403, Tbilisi
Site 404, Tbilisi
Site 405, Tbilisi
Site 406, Tbilisi
Site 407, Tbilisi
Site 802, Balassagyarmat
Site 801, Budapest
Site 803, Debrecen
Site 804, Kistarcsa
Site 805, Törökbálint
Site 901, Chrzanów
Site 904, Krakow
Site 902, Oświęcim
Site 903, Łęczna
Site 506, Moscow
Site 510, Moscow
Site 507, Saint Petersburg
Site 508, Saint Petersburg
Site 509, Saint Petersburg
Site 703, Belgrade
Site 704, Belgrade
Site 705, Belgrade
Site 707, Belgrade
Site708, Belgrade
Site 706, Kamenitz
Site 701, Kragujevac
Site 702, Niš
Site 606, Dnipro
Site 602, Kharkiv
Site 604, Kharkiv
Site 611, Kharkiv
Site 603, Kyiv
Site 605, Kyiv
Site 607, Kyiv
Site 609, Kyiv
Site 608, Zaporizhia
Site 610, Zaporizhia
Lead Sponsor
Paratek Pharmaceuticals Inc
INDUSTRY